LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Search

TransMedics Group Inc

Gesloten

SectorGezondheidszorg

129.66 -7.32

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

128.48

Max

136.46

Belangrijke statistieken

By Trading Economics

Inkomsten

81M

105M

Verkoop

17M

161M

K/W

Sectorgemiddelde

57.874

66.845

Winstmarge

65.551

Werknemers

898

EBITDA

-916K

32M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+13.37% upside

Dividenden

By Dow Jones

Volgende Winsten

7 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

422M

5B

Vorige openingsprijs

136.98

Vorige sluitingsprijs

129.66

Nieuwssentiment

By Acuity

50%

50%

154 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

TransMedics Group Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 aug 2025, 19:15 UTC

Belangrijke Marktbewegers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Peer Vergelijking

Prijswijziging

TransMedics Group Inc Prognose

Koersdoel

By TipRanks

13.37% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 158.8 USD  13.37%

Hoogste 190 USD

Laagste 115 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor TransMedics Group Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

8

Buy

3

Hold

0

Sell

Technische score

By Trading Central

92.43 / 94.18Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

154 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat